Treace Medical price target lowered to $25 from $27 at Stephens

Stephens analyst George Sellers lowered the firm’s price target on Treace Medical to $25 from $27 and keeps an Equal Weight rating on the shares. The company reported Q2 revenue and gross margins that were above consensus, the analyst tells investors. While this was a “strong quarter” for the company and its valuation has become “more attractive,” Stephens would prefer the recent volatility to fully pass before becoming more constructive on the stock.